Evidence map›Paper›PMID 31143438›Full record

ArticleParkinson's disease2019

Patient Knowledge and Attitudes towards Genetic Testing in Parkinson's Disease Subjects with Deep Brain Stimulation.

Avram Fraint, Bichun Ouyang, Leonard Verhagen Metman, Carolyn Jones, Deborah A Hall, Karen Marder, Gian Pal

Open access · goldAbstract read
In one paragraph

Article in Parkinson's disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Genetic Testing in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Avram FraintDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Bichun OuyangDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Leonard Verhagen MetmanDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Carolyn JonesDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Deborah A HallDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Karen MarderDepartment of Neurology and the Taub Institute, Columbia University Medical Center, New York, NY, USA.
Gian PalDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.ORCID 0000-0003-1048-6182
Rush University Medical Center · USColumbia University Irving Medical Center · US

Funding

Parkinson disease and DBS: cognitive effects in GBA mutation carriersK23NS097625 · NINDS · RUSH UNIVERSITY MEDICAL CENTER · PI PAL, GIAN D · 2017 to 2021
$936k
NINDS NIH HHS K23 NS097625NINDS NIH HHS L30 NS103289
6 · The paper itself

Abstract

objectivesAs genetic testing is becoming more widely commercially available for Parkinson's disease (PD) and may have implications regarding clinical outcomes for deep brain stimulation (DBS) and other therapies, we aimed to determine patient knowledge and attitudes towards genetic testing.

methodsA sample of 88 PD subjects with bilateral STN-DBS completed a Genetic Attitudes Questionnaire (GAQ). Knowledge and attitudes towards genetic testing were assessed.

resultsThe mean percent of correct responses regarding genetic testing knowledge was 58.5%. Nearly 90% of subjects were unfamiliar with Genetic Information Nondiscrimination Act (GINA). The most important reasons subjects cited in deciding whether to undergo genetic testing included (1) to be a candidate for clinical trials if positive, (2) to learn that they do not carry a mutation, and (3) because a healthcare provider had recommended it. Individuals who influence decision-making include spouses and children. About 88% of subjects would share results with spouses, children, and siblings. DISCUSSION: These results reveal that there is a major knowledge gap regarding genetic testing in PD and the implications of testing results on treatment, work, insurance, and privacy. Also, subjects would mainly seek genetic testing to participate in clinical trials, with spouses and children being the key stakeholders in decision-making.

Identifiers

PMID31143438
PMCPMC6501170
OpenAlexW2937187675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.